


PHARMACEUTICAL 2018



HERON THERAPEUTICS INC. DE Rank 261 of 349





PHARMACEUTICAL 2018



HERON THERAPEUTICS INC. DE Rank 261 of 349

The relative strengths and weaknesses of HERON THERAPEUTICS INC. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HERON THERAPEUTICS INC. DE compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 98% points. The greatest weakness of HERON THERAPEUTICS INC. DE is the variable Research and Development, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is -390%, being 112% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	228,063
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	103,171
Liabilities, Non-Current	0
Other Assets	263
Other Compr. Net Income	7.0
Other Expenses	61,189
Other Liabilities	0
Other Net Income	-2,926
Property and Equipment	5,981
Research and Development	138,582
Revenues	30,767
Selling, General and Administrative Expense	25,554

Output Variable	Value in 1000 USD
Assets	234,307
Liabilities	103,171
Expenses	225,325
Stockholders Equity	131,136
Net Income	-197,484
Comprehensive Net Income	-197,480
Economic Capital Ratio	-390%